Disclosure(s): No relevant financial relationship(s) to disclose.
Disclosure(s):
Jody Olson, MD, FACP, FCCM: No relevant financial relationship(s) to disclose.
In this section, the pathophysiology behind developing AKI in ACLF will be discussed. There will be a focused discussion on hepatorenal syndrome and emerging approaches to its management including the use of terlipressin.
